# Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer

> **NCT02324088** · PHASE3 · COMPLETED · sponsor: **UNICANCER** · enrollment: 174 (actual)

## Conditions studied

- Inflammatory Breast Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Cyclophosphamide
- **DRUG:** Epirubicin

## Key facts

- **NCT ID:** NCT02324088
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-10
- **Primary completion:** 2012-12
- **Final completion:** 2015-01
- **Target enrollment:** 174 (ACTUAL)
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02324088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02324088, "Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02324088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*